These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36018830)

  • 1. Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat
    Singla A; Simbassa SB; Chirra B; Gairola A; Southerland MR; Shah KN; Rose RE; Chen Q; Basharat A; Baeza J; Raina R; Chapman MJ; Hassan AM; Ivanov I; Sen A; Wu HJ; Cannon CL
    ACS Appl Mater Interfaces; 2022 Sep; 14(36):40724-40737. PubMed ID: 36018830
    [No Abstract]   [Full Text] [Related]  

  • 2. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
    Bakker-Woudenberg IA; ten Kate MT; Guo L; Working P; Mouton JW
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2575-81. PubMed ID: 12121935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study.
    Derbali RM; Aoun V; Moussa G; Frei G; Tehrani SF; Del'Orto JC; Hildgen P; Roullin VG; Chain JL
    Mol Pharm; 2019 May; 16(5):1906-1916. PubMed ID: 30900903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
    VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
    Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.
    Wang S; Yu S; Lin Y; Zou P; Chai G; Yu HH; Wickremasinghe H; Shetty N; Ling J; Li J; Zhou QT
    Pharm Res; 2018 Aug; 35(10):187. PubMed ID: 30094660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of Farnesol Significantly Increases the Efficacy of Liposomal Ciprofloxacin against Pseudomonas aeruginosa Biofilms in Vitro.
    Bandara HM; Herpin MJ; Kolacny D; Harb A; Romanovicz D; Smyth HD
    Mol Pharm; 2016 Aug; 13(8):2760-70. PubMed ID: 27383205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.
    Chai G; Park H; Yu S; Zhou F; Li J; Xu Q; Zhou QT
    Int J Pharm; 2019 Oct; 569():118616. PubMed ID: 31415873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-microbial Effect and in Vivo Ocular Delivery of Ciprofloxacin-loaded Liposome through Rabbit's Eye.
    Feghhi M; Sharif Makhmalzadeh B; Farrahi F; Akmali M; Hasanvand N
    Curr Eye Res; 2020 Oct; 45(10):1245-1251. PubMed ID: 32045531
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel pyochelin-based PEGylated liposomes for enhanced delivery of antibiotics against resistant clinical isolates of Pseudomonas aeruginosa.
    Pushparaj Selvadoss P; Nellore J; Balaraman Ravindrran M; Sekar U
    Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2043-2053. PubMed ID: 29179607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents.
    Cook PP; Das TD; Gooch M; Catrou PG
    Infect Control Hosp Epidemiol; 2008 Aug; 29(8):716-22. PubMed ID: 18590455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.
    Ong HX; Traini D; Cipolla D; Gonda I; Bebawy M; Agus H; Young PM
    Pharm Res; 2012 Dec; 29(12):3335-46. PubMed ID: 22833052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.
    Omri A; Suntres ZE; Shek PN
    Biochem Pharmacol; 2002 Nov; 64(9):1407-13. PubMed ID: 12392822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
    Khan M; Ma K; Wan I; Willcox MD
    Cont Lens Anterior Eye; 2023 Jun; 46(3):101819. PubMed ID: 36732125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa isolated from drinking water and hospitalized patients in Jordan.
    Tarazi YH; Abu-Basha E; Ismail ZB; Al-Jawasreh SI
    Acta Trop; 2021 May; 217():105859. PubMed ID: 33582141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
    Serisier DJ; Bilton D; De Soyza A; Thompson PJ; Kolbe J; Greville HW; Cipolla D; Bruinenberg P; Gonda I;
    Thorax; 2013 Sep; 68(9):812-7. PubMed ID: 23681906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer.
    Li JJ; Hu Y; Hu B; Wang W; Xu H; Hu XY; Ding F; Li HB; Wang KR; Zhang X; Guo DS
    Nat Commun; 2022 Oct; 13(1):6279. PubMed ID: 36270992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.